Module 9 Therapeutic Index Flashcards

1
Q

Interpatient Response Variability

A
  • Response to medication unique
  • Evaluation ensure therapeutic response
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Medication Response Influences

A
  • Genetics
  • Disease state
  • Environment
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Determining Interpatient Variability

A
  • Clinical trails
  • Setting an end point
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Phase 1

A
  • 20 - 100 volunteers
  • Animal studies guide dosing
  • Evaluate pharmacokinetics & pharmacodynamics
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Phase 2

A
  • 300-500 with disorder
  • Determine dose-response over range of doses
  • Short term trial
  • Efficacy & side effects
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Phase 3

A
  • 500-5000 with disorder
  • Verify efficacy
  • Evaluate long term side effects
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Phase 4

A
  • Post-marketing surveillance
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Data Collection

A
  • Plot on frequency distribution curve
  • Average effective dose (ED50)
  • Peak of curve
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

ED50

A
  • Required dose to produce response 50% of people
  • Used as initial dose in therapy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

ED50 Wide Range

A
  • Use ED50 measurement for initial dose
  • Monitor patient response
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

ED50 Narrow Range

A
  • Titrate dose ED50 dose
  • Start low & increase until response achieved
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Dosing Implications

A
  • Dose adjustments from ED50 for effective therapy
  • Patient response
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Toxic Doses TD50

A
  • Animals used for testing
  • Short term & chronic
  • 50% of tested animals experience toxicity
  • Drug/kg of body weight
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Lethal Doses LD50

A
  • 50% of tested animals experience death
  • Drug/kg of body weight
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Therapeutic Index

A
  • Indicator of drug safety
  • Ratio of LD50/TD50 to ED50 (division)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

High Index

A
  • Safe drug
  • Large space between therapeutic & toxic dose
17
Q

Low Index

A
  • Unsafe drug
18
Q

Affecting Factors of Interpatient Response Variation

A
  • Genetics
  • Sex
  • Race
  • Kidney disease
  • Liver disease
  • Environment
19
Q

Body Weight/Composition

A
  • Adjust dose for body weight
  • Body fat % can alter distribution
  • Adjust dose for body surface area (BSA)
  • BSA accounts better for composition
20
Q

Genetics

A
  • DNA sequence variation in drug response
  • SNP change in DNA in regulating drugs
  • Explain intrasubject variation
  • Adjust dose for genotype
21
Q

Sex

A
  • Slower alcohol metabolism in females
  • Opioids more effective in women
  • QT interval prolonged in women (cardiac dysrhythmia)
22
Q

Race

A
  • Many races in each individual
  • Unable to categorize in a single race
  • Rosuvastatin high in Asians (decrease cholesterol)
23
Q

Kidney Disease

A
  • Primary drug elimination
  • Deceased drug excretion
  • Increases half life of renally excreted drugs
  • Decrease hepatic & intestinal metabolism
  • Increases oral bioavailability
  • Lower doses
24
Q

Liver Disease

A
  • Primary drug metabolism
  • Decreased hepatic metabolism
  • Increased half life
25
Q

Environment

A
  • Change response to drug
  • Voluntary/involuntary
  • Alcohol, smoke, exercise, pesticides
26
Q

Pesticide Exposure

A
  • Induce CYPs
  • Decrease drug response in CYP metabolizing enzymes